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Abstract The mechanisms through which cancer cells lock in altered transcriptional programs in 
support of metastasis remain largely unknown. Through integrative analysis of clinical breast cancer 
gene expression datasets, cell line models of breast cancer progression, and mutation data from 
cancer genome resequencing studies, we identified RNA binding motif protein 47 (RBM47) as a 
suppressor of breast cancer progression and metastasis. RBM47 inhibited breast cancer re-initiation 
and growth in experimental models. Transcriptome-wide HITS-CLIP analysis revealed widespread 
RBM47 binding to mRNAs, most prominently in introns and 3′UTRs. RBM47 altered splicing and 
abundance of a subset of its target mRNAs. Some of the mRNAs stabilized by RBM47, as exemplified by 
dickkopf WNT signaling pathway inhibitor 1, inhibit tumor progression downstream of RBM47. Our 
work identifies RBM47 as an RNA-binding protein that can suppress breast cancer progression and 




Cancers arise through an evolutionary process that feeds from stochastic genetic alterations and 
selection (Vogelstein et al., 2013). The identities of the alterations that get selected for are rapidly 
coming to light through large-scale resequencing efforts. For example, several independent studies 
have characterized the mutational complement of breast cancer, one of the most common human 
malignancies (Shah et al., 2009; Stephens et al., 2009; Ding et al., 2010; Banerji et al., 2012; 
Cancer Genome Atlas Network, 2012; Shah et al., 2012; Stephens et al., 2012). Besides confirming 
previously known cancer genes, such as TP53 and PIK3CA, most studies also report a long tail of 
rarely mutated genes. While many of these mutations are likely to be passenger events, some of them 
are potential mediators of tumor phenotypes. How to identify such low-frequency driver mutations 
remains a challenge.
In addition to mutations that directly promote tumorigenesis through specific alterations in cell 
signaling and repair pathways, many aberrations found in cancers do not affect cell signaling pathways 
directly, but rather, they support the stabilization of altered transcriptomic profiles that facilitate 
the emergence of pro-tumorigenic and metastatic traits. Mutations in epigenetic regulators fall into 
this category (Shen and Laird, 2013). The phenotypic output of such alterations would depend on 




†These authors contributed 
equally to this work
Competing interests: See page 19
Funding: See page 19
Received: 07 March 2014
Accepted: 31 May 2014
Published: 04 June 2014
Reviewing editor: Roy Parker, 
University of Colorado, United 
States
 Copyright Vanharanta et al. 
This article is distributed under 
the terms of the Creative 
Commons Attribution License, 
which permits unrestricted use 
and redistribution provided that 
the original author and source 
are credited.
RESEARCH ARTICLE
Genes and chromosomes | Human biology and medicine
Vanharanta et al. eLife 2014;3:e02734. DOI: 10.7554/eLife.02734 2 of 24
Research article
that result in a phenotypic trait in the presence of a specific transcriptional program have been 
described (Vanharanta et al., 2013). Analogously, aberrations in the multi-step mRNA processing 
and turnover cascade (Moore and Proudfoot, 2009) could also lock in aberrant transcriptomic 
states.
Precise regulation of RNA metabolism is fundamental in the generation of biological complexity in 
both normal and disease states (Sharp, 2009; Licatalosi and Darnell, 2010). The concerted action 
of multiple RNA binding proteins (RBPs) regulate the spatial, temporal and functional dynamics of 
the transcriptome via alternative splicing, alternative polyadenylation and transcript stability 
(Moore and Proudfoot, 2009). While malignancy-associated dysregulation of RNA metabolism 
via aberrant microRNA expression is relatively well established (Di Leva et al., 2013; Pencheva 
and Tavazoie, 2013), a growing body of evidence indicates a prominent role also for RBPs in both 
the development and progression of cancer. For example, upregulation of the splicing regulator 
SRSF1 is associated with multiple tumor types (Karni et al., 2007), and is necessary for the onco-
genic activity of MYC in lung cancer (Das et al., 2012). Conversely, RBM5 has been shown to be 
tumor suppressive in several cancer models (Oh et al., 2002; Mourtada-Maarabouni et al., 2006; 
Oh et al., 2006).
We hypothesized that combining cancer genome resequencing data with gene expression informa-
tion from both clinical data sets and experimental model systems of metastasis would allow the iden-
tification of rarely mutated cancer genes with potential functional significance. This approach identified 
RNA binding motif protein 47 (RBM47) as a suppressor of breast cancer progression. By analyzing the 
transcriptome-wide RBM47 binding patterns we demonstrate that RBM47, a previously uncharacter-
ized RNA-binding protein, modulates mRNA splicing and stability. Loss of RBM47 function thus pro-
vides a specific example of the power of global RNA modulatory events in the selection of pro-metastatic 
phenotypic traits.
Results
RBM47 inactivation associated with breast cancer progression
We combined gene expression data from triple negative metastatic breast cancer models (Minn et al., 
2005; Bos et al., 2009) and a cohort of 368 untreated clinical breast cancer cases (Minn et al., 2005; 
eLife digest Tumors form when mistakes in the genes of a single cell allow it to multiply 
uncontrollably. Sometimes further mutations in genes allow the cancerous cells to escape from the 
tumor, enter the bloodstream and start a second cancer elsewhere in the body. However, many of 
the genetic changes behind this process, which is called metastasis, are poorly understood—
especially those changes in genes that occur rarely, but can still help the cancer to spread.
Vanharanta, Marney et al. have looked at data on which genes are switched ‘on’ or ‘off’ in 
metastatic breast cancer cells. A gene called RBM47 was often switched off in these cells, and 
patients with a low level of RBM47 tended to have a poor clinical outcome.
To test the function of the gene, Vanharanta, Marney et al. switched on RBM47 in cancer cells 
that had spread from the breast to either the lungs or the brain, and then injected these cells into 
mice. Few of these cells were able to invade lung and brain tissues in the mice. However, switching 
off the RBM47 gene in breast cancer cells had the opposite effect; these cells invaded the lungs of 
mice more efficiently.
RBM47 encodes a protein that sticks to molecules of messenger RNA: molecules that transport 
the instructions encoded in DNA to the machinery that builds proteins. Vanharanta, Marney et al. 
found that the wild-type RBM47 protein increased the levels of 102 different messenger RNA 
molecules, but decreased the levels of another 92. Further experiments showed that RBM47 also 
slows the rate at which messenger RNA molecules are broken down inside cells: this results in the 
accumulation of proteins that slow down the growth of tumors. Without RBM47, tumor growth is 
unleashed. Further work is needed to test if increasing RBM47 activity could be used as a new 
treatment for some types of cancer.
DOI: 10.7554/eLife.02734.002
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Figure 1. RBM47 expression associated with breast cancer progression. (A) A schematic of the analytical approach. 
Genes identified as mutated in a breast cancer brain metastasis by Ding et al. (2010) where compared to metastasis-
associated gene expression traits in both clinical data sets and experimental model systems. This identified RBM47 
as a putative breast cancer suppressor gene. (B) RBM47 mRNA expression measured by quantitative real-time 
RT-PCR in two cell line systems of breast cancer metastasis. In both panels, the data are normalized to the parental 
cell line (Par). Error bars represent 95% confidence intervals obtained from multiple PCR reactions. LM, lung metastatic 
derivative; BoM, bone metastatic derivative; BrM, brain metastatic derivative. (C) RBM47 protein expression measured 
by Western blotting. Samples as in (B). Tubulin used as a loading control. (D) Brain metastasis free survival in a cohort 
of 368 untreated breast cancer patients. Cases classified based on RBM47 mRNA expression, bottom 1/3 in blue, 
top 2/3 in red. p-value derived from a Cox proportional hazards model using RBM47 expression as a continuous 
variable. (E) Lung metastasis free survival in a cohort of 368 untreated breast cancer patients. Cases classified based 
on RBM47 mRNA expression, bottom 1/3 in blue, top 2/3 in red. p-value derived from a Cox proportional hazards 
model using RBM47 expression as a continuous variable. (F) Bone metastasis free survival in a cohort of 368 untreated 
breast cancer patients. Cases classified based on RBM47 mRNA expression, bottom 1/3 in blue, top 2/3 in red. 
p-value derived from a Cox proportional hazards model using RBM47 expression as a continuous variable.(G) RBM47 
expression as measured by RNA-seq in the TCGA data set of 748 patients. Samples grouped based on breast 
cancer molecular subtype: luminal A, luminal B, Her2 positive, claudin low and basal. RBM47 expression is lower in 
claudin low and basal subtypes, both of which are associated with poor patient outcome. (H) A schematic showing 
the predicted protein structure of RBM47, its closest homologue A1CF, a known RNA-binding protein, and the 
predicted structure of RBM47I281fs mutant. Blue diamonds represent RRM motifs, pink rectangle represents a truncated 
RRM motif.
DOI: 10.7554/eLife.02734.003
The following figure supplements are available for figure 1:
Figure supplement 1. RBM47 expression and genetic alterations in human breast cancer.
DOI: 10.7554/eLife.02734.004
Genes and chromosomes | Human biology and medicine
Vanharanta et al. eLife 2014;3:e02734. DOI: 10.7554/eLife.02734 4 of 24
Research article
Wang et al., 2005) with mutational data from a brain metastasis that originated from a basal breast 
cancer (Ding et al., 2010; Figure 1A). Specifically, we looked for genes that had reduced mRNA 
expression in functionally metastatic cancer cells, evidence for low mRNA expression associated 
with poor patient outcome in clinical samples, and an enriched mutation in the brain metastasis 
sequenced by Ding et al. (2010). RBM47, a gene encoding a previously uncharacterized putative 
RNA-binding protein was the only one that fulfilled all these criteria (Baltz et al., 2012; Castello et al., 
2012; Ray et al., 2013). We confirmed the lower expression of RBM47 mRNA in the highly metastatic 
cells (Figure 1B). This translated into a comparable difference at the protein level (Figure 1C). In the 
clinical data sets, low RBM47 mRNA expression was significantly associated with relapse to brain and 
lung (Figure 1D,E) but not to bone (Figure 1F). In multivariate analysis combining RBM47 expression 
with estrogen, progesterone and HER2 receptor status (ER, PR and HER2), the association with brain 
metastasis remained statistically significant (Figure 1—figure supplement 1A). We further character-
ized the expression patterns of RBM47 in the TCGA cohort of 748 breast cancer samples studied by 
RNA-seq (Cerami et al., 2012; Cancer Genome Atlas Network, 2012). We found that low RBM47 
expression was significantly associated with claudin-low and basal breast cancers (Figure 1G), two 
subtypes of poor prognosis (Smid et al., 2008; Lu et al., 2013).
The RBM47I281fs mutation first reported in a brain metastasis truncates the protein from the third 
RNA recognition motif (RRM) onwards (Figure 1H). As this mutation was already present in a minority 
subpopulation of the corresponding primary tumor (Ding et al., 2010), we looked for additional 
evidence of genetic RBM47 aberrations in primary breast cancer cohorts. The catalogue of somatic 
mutations in cancer (COSMIC) database (Forbes et al., 2010) reported 9 non-synonymous mutations 
in RBM47, three of which were frameshift mutations truncating one or more of the RRM domains 
(Figure 1—figure supplement 1B). Furthermore, analysis of the data from the TCGA cohort revealed 
that in basal breast cancer, RBM47 was targeted by a mutation or homozygous deletion in ∼8% of the 
cases (Figure 1—figure supplement 1C). Moreover, heterozygous loss of the RBM47 locus was 
present in 30% of the TCGA cohort (Cerami et al., 2012). These correlative analyses of multiple 
different breast cancer data sets, both experimental systems and large clinical patient cohorts, sug-
gested that reduced expression or function of RBM47 is associated with breast cancer progression 
already within primary tumors, and that clones with reduced RBM47 function may display enhanced 
lung and brain metastatic fitness.
RBM47 suppresses breast cancer progression
In order to test the role of RBM47 as a suppressor of breast cancer progression, we stably intro-
duced both wild type RBM47 and RBM47I281fs in the lung metastatic (LM2) and brain metastatic 
(BrM2) derivatives of the MDA-MB-231 triple negative breast cancer cells (MDA231 for short), 
respectively (Figure 2—figure supplement 1A; Minn et al., 2005; Bos et al., 2009). Of note, 
despite robust mRNA expression, the mutant RBM47I281fs protein levels were low, indicating that 
the mutant protein was unstable and therefore inactive (Figure 2—figure supplement 1B). 
As determined by in vivo bioluminescence in experimental metastasis assays, wild type RBM47 
inhibited lung colonization by the MDA231-LM2 cells, when compared to RBM47I281fs (Figure 2A–B). 
Similarly, we observed extended brain metastasis free survival in mice inoculated with the 
MDA231-BrM2 cells expressing RBM47 when compared to those expressing RBM47I281fs (Figure 2C). 
This difference translated into reduced brain metastatic burden as determined by ex vivo imaging 
(Figure 2D,E, Figure 2—figure supplement 1C). We then tested the effects of inhibiting endog-
enous RBM47 in the metastatic colonization of the parental MDA231 cells. With comparable 
effects of RBM47 re-expression seen in both the lung and brain metastasis models (Figure 2A,E), 
we chose the lung colonization assay for loss-of-function studies as this allowed the simultaneous 
analysis of a greater number of tumor re-initiation events. Two RBM47-targeting shRNA constructs 
significantly shortened the lung metastasis free survival in mice when compared to controls 
(Figure 2F, Figure 2—figure supplement 1D), as determined by bioluminescence imaging 
(Figure 2G,H). This result was confirmed with a second more indolent cancer cell clone (Figure 2—
figure supplement 1E–G).
Clonal heterogeneity in RBM47 sensitivity
The initial functional experiments suggested that the tumor suppressive effect of RBM47 on the 
overall population of metastatic cancer cells was modest. This could reflect either weak tumor 
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Figure 2. RBM47 suppresses metastatic breast cancer progression. (A) Normalized lung photon flux in mice after 
tail vein inoculation of MDA231-LM2 cells expressing either wild type RBM47 or RBM47I281fs. p-value calculated 
utilizing repeated measures two-way ANOVA. N = 6 for RBM47I281fs, N = 8 for RBM47. (B) Representative biolumi-
nescence images from the experiment shown in (A). The color scale shows bioluminescence (photons/second).  
(C) Brain metastasis free survival as determined by in vivo bioluminescence imaging in mice after intracardiac 
inoculation of MDA231-BrM2 cells expressing either wild type RBM47 or RBM47I281fs. p-value calculated using  
the log-rank test. N = 9 for RBM47I281fs, N = 7 for RBM47. (D) Representative bioluminescence images from the 
experiment shown in (C). The color scale shows bioluminescence (photons/second). (E) Ex vivo quantification of 
bioluminescence from brain metastases on day 42 of the experiment shown in panel (C). P-value calculated by 
two-tailed Student's t test. (F) Lung metastasis free survival as determined by in vivo bioluminescence imaging in 
mice after tail vein inoculation of parental MDA231 cells expressing either control vector (pGIPZ) or hairpins against 
RBM47 (shRNA1 and shRNA2). p-values calculated using the log-rank test. N = 8 for Ctrl group, N = 6 for shRNA1, 
N = 5 for shRNA2. (G) In vivo bioluminescence imaging on day 36 of the experiment shown in (F) demonstrates earlier 
emergence of detectable lung metastasis for the RBM47 knockdown groups when compared to the control 
animals. The color scale shows bioluminescence (photons/second). (H) Quantification of bioluminescence for the 
time point shown in (G). Data normalized to signal on day 0 for each animal. p-value calculated using the Wilcoxon 
rank-sum test.
DOI: 10.7554/eLife.02734.005
The following figure supplements are available for figure 2:
Figure supplement 1. RBM47 suppresses breast cancer progression.
DOI: 10.7554/eLife.02734.006
suppressive function of RBM47 in general, heterogeneity in the sensitivity to RBM47 among dif-
ferent cancer cell subpopulations, or in the case of RBM47 reintroduction, loss of transgene expres-
sion. In order to distinguish between these possibilities, we used immunohistochemistry to assess 
RBM47 expression in the lung nodules formed either by wild type RBM47 or RBM47I281fs express-
ing cells. This revealed that some cancer clones were able to form robust lung metastasis even in 
the presence of RBM47 (Figure 3A, Figure 3—figure supplement 1A), but that many of the 
metastases formed after the inoculation of wild type RBM47-expressing cells had avoided or sup-
pressed the expression of RBM47 (Figure 3B, Figure 3A—figure supplement 1A). As expected, 
the RBM47I281fs-expressing tumors contained only weakly staining cancer cells intermingled with 
small cells with strong RBM47 expression (Figure 3C), similar to those seen in normal lung paren-
chyma (Figure 3D). The rate of proliferation as determined by Ki67 immunohistochemistry did not 
correlate with the level of RBM47 expression (Figure 3—figure supplement 1A). This was in line 
with the idea that some clones were more sensitive to RBM47 than others, but also that a strong 
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Figure 3. Clonal heterogeneity in RBM47 sensitivity. (A) A lung metastatic nodule with strong RBM47 expression in 
a mouse inoculated with RBM47-transduced MDA231-LM2 cells. RBM47 protein expression detected by immuno-
histochemistry using an antibody against RBM47. (B) A lung metastatic nodule with weak RBM47 expression in a 
mouse inoculated with RBM47-transduced MDA231-LM2 cells. RBM47 protein expression detected by immunohis-
tochemistry. Note the clearly reduced staining when compared to panel (A). (C) A lung metastatic nodule with weak 
RBM47 expression in a mouse inoculated with RBM47I280fs-transduced MDA231-LM2 cells. RBM47 protein expres-
sion detected by immunohistochemistry. Staining intensity similar to that seen in panel (B). (D) RBM47 expression in 
normal mouse lung. RBM47 protein expression detected by immunohistochemistry. Note small cells with strong 
RBM47 expression, similar to those seen in panels (B) and (C). (E) Brain metastasis free survival as determined by in 
vivo bioluminescence imaging in mice after intracardiac inoculation of WT10 cells. The RBM47 group received 
doxycycline in diet. p-value calculated using the log-rank test. N = 9 for both groups. (F) Representative ex vivo 
bioluminescence images from brain metastasis of the experiment shown in (E). The color scale shows biolumines-
cence (photons/second). (G) Ex vivo quantification of bioluminescence from brain metastases with and without 
RBM47 reintroduction. WT10 data from the experiment shown in (E). WT6 data from a similar experimental setup. 
p-value calculated by two-tailed Student's t test. N = 9 for Ctrl group, N = 10 for RBM47 group. (H) Brain metastasis 
free survival as determined by in vivo bioluminescence imaging in mice after intracardiac inoculation of MUT3 cells. 
The I281fs group received doxycycline in diet. p-value calculated using the log-rank test. N = 9 for Ctrl group, N = 7 
for RBM47I281fs group. (I) Representative ex vivo bioluminescence images from brain metastases of the experiment 
shown in (H). The color scale shows bioluminescence (photons/second). (J) Ex vivo quantification of biolumines-
cence from brain metastases of the experiment shown in (H). p-value calculated by two-tailed Student's t test.
DOI: 10.7554/eLife.02734.007
The following figure supplements are available for figure 3:
Figure supplement 1. RBM47 expression in experimental metastases.
DOI: 10.7554/eLife.02734.008
Figure supplement 2. Model systems with inducible RBM47 expression.
DOI: 10.7554/eLife.02734.009
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selective pressure led metastatic cells to lose RBM47, a finding consistent with the initial observa-
tion of RBM47 loss in metastatic cell populations (Figure 1C).
In order to allow better experimental control over RBM47 expression we utilized a conditional 
expression system. By focusing on the two brain metastatic cell lines that expressed the lowest levels 
of endogenous RBM47 (Figure 1C) we generated single cell-derived clones with doxycycline-inducible 
expression of either wild type RBM47 (henceforth WT10 and WT6, respectively) or the patient-derived 
mutant RBM47I281fs (henceforth MUT3). All clones exhibited dose-dependent RBM47 mRNA upregu-
lation upon doxycycline induction (Figure 3—figure supplement 2A–C) that translated into increased 
RBM47 protein expression in the wild type-expressing clones (Figure 3—figure supplement 2D,E). 
Cancer cells also tolerated RBM47 in vitro (Figure 3—figure supplement 2F). After confirming the 
feasibility of doxycycline-mediated conditional gene activation in metastatic brain lesions (Figure 3—
figure supplement 2G), we inoculated WT6, WT10 and MUT3 cells into immunocompromized mice 
and assessed their brain-metastatic phenotype. All clones formed robust brain metastases under 
doxycycline-free conditions (Figure 3E–J). The induction of RBM47 expression with doxycycline 
in the diet inhibited robustly brain colonization of both metastatic cell clones, WT6 and WT10 
(Figure 3E–G). However, the patient-derived mutant RBM47I281fs did not show any tumor suppressive 
effects (Figure 3H–J). Collectively, these results demonstrated that RBM47 was able to strongly inhibit 
metastatic functions of some cancer clones, whereas other clones were able to form metastasis despite 
the presence of RBM47.
Transcriptome-wide identification of RBM47 binding sites
To determine whether RBM47 can directly bind RNA in vivo, we made use of the ability of 
UV-irradiation at 254 nm to induce chemical crosslinks between RNA and proteins that are in 
direct contact (Darnell, 2010). γ-32P-labeled RNA was detected by autoradiogram at ∼76 kD, the 
predicted size of Flag-RBM47, in Flag-immunoprecipitates from UV-irradiated, doxycycline-treated 
MDA231-BrM2 WT Flag-RBM47 cells, but not doxycycline-treated empty vector control or non-
irradiated WT Flag-RBM47 expressing cells (Figure 4A). To identify directly bound RBM47 targets, 
a modified version of the high throughput sequencing and cross-linking immunoprecipitation 
(HITS-CLIP) protocol (Licatalosi et al., 2008; Weyn-Vanhentenryck et al., 2014) was carried out 
in duplicate on Flag-RBM47 expressing MDA231-BrM2 cells treated with doxycycline. (Figure 4B, 
see 'Materials and methods'). RBM47-bound HITS-CLIP reads were mapped to the human genome, 
yielding ∼7.7 × 106 and ∼2.0 × 106 unique reads (tags) per replicate. 75% of the tags mapped to 
regions corresponding to UCSC/Refseq genes, with a high degree of reproducibility of binding 
observed between replicates (Spearmann correlation coefficient R2 = 0.998, total tags per gene, 
Figure 4C).
To identify robust and reproducible RBM47-binding sites, tags were clustered to return regions 
with evidence of binding in both replicates (biological complexity, BC = 2) with increasingly stringent 
filters (Figure 4D): tags per cluster (tags ≥2, 617,026 clusters; tags ≥10, 94,966 clusters), a previ-
ously described significant peak threshold (significant peak height ≥10, 29,562 clusters [Chi et al., 
2009]), and a ranked reproducibility chi-squared score (p≤0.01, 19,433 clusters [Darnell et al., 
2011]). As has been previously described for the n-ELAV proteins (Ince-Dunn et al., 2012), iden-
tification of the most robust binding through increased stringency of cluster definition led to an 
increase in proportional binding in 3′UTR regions. For RBM47 this occurred due to loss of the 
majority of reproducible, yet relatively small intronic binding sites (Figure 4E), which may reflect 
the relative abundance of pre- and mature RNA message. Motif analysis (MEME, Bailey and Elkan, 
1994) failed to identify an enriched RBM47-binding sequence in ±10 nt footprints centered on the 
top 3000 significant peaks (data not shown), but revealed a polyU sequence enriched in RBM47-
binding sites containing cross-link induced mutations (deletion CIMS, Zhang and Darnell, 2011, 
Figure 4F). The apparent lack of an enriched RBM47-binding motif within robust CLIP-derived 
binding sites may reflect the broad binding patterns observed, as exemplified by the predomi-
nantly 3′UTR binding in DKK1 and IL8 (Figure 4G).
RBM47 regulates alternative splicing
Reproducible binding of RBPs in intronic regions has proven to be predictive of a role in pre-mRNA 
processing for multiple proteins. To explore the relationship between RBM47 intronic binding and 
alternative splicing, RNA-seq was carried out in triplicate to compare MDA231-BrM2 cells and 
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Figure 4. HITS-CLIP identifies genome-wide RBM47 binding maps. (A) Radiolabelled RNA is detectable in 
RBM47-expressing 231-BrM2 metastatic cells that have been UV-irradiated indicating in vivo RNA binding ability. 
No RNA is detected in non-crosslinked cells despite the presence of ample immunoprecipitated Flag-RBM47 
protein. No RNA or protein is detected in control 231-BrM2 transduced with empty vector. Samples run in 
duplicate. (B) Schematic of the modified HITS-CLIP protocol showing autoradiogram of duplicate Flag-RBM47 
samples used. Purified RBM47-bound RNA fragments (green) were polyA tailed and reverse transcribed in the 
presence of Brd-U using a polydT-NV primer encoding the full sense sequence of the Illumina reverse sequencing 
primer (blue), an abasic furan that serves as an ApeI cut site (ξ), a partial reverse complement to the Illumina 
forward sequencing primer (orange), and two hexamer sequences (purple): a known-sequence index for multiplex-
ing and a degenerate barcode used to distinguish unique cDNA clones from PCR duplicates. cDNA were 
Figure 4. Continued on next page
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RBM47-expressing WT10 cells. Reads were mapped to cassette (CA) exon junctions as described pre-
viously for Mbnl2 (Charizanis et al., 2012), and an average inclusion rate (IR) calculated for each cell 
type to allow for the identification of reciprocal splicing changes while normalizing for changes in RNA 
stability (Ule et al., 2005; Figure 5A). The average change in inclusion rate (ΔI) was then calculated 
such that positive ΔI indicates RBM47-dependent cassette exon inclusion. This analysis revealed 121 
and 140 CA exons with significant RBM47-dependent inclusion and exclusion, respectively. To assess 
whether RBM47-binding occurred in the vicinity of these splice sites, HITS-CLIP tags in BC2 tags ≥5 
clusters (to account for lower levels of intronic binding seen in Figure 4E) in the region of the alterna-
tive splice were calculated. Forty-eight RBM47-bound included and 49 RBM47-bound excluded CA 
exons were identified in a total of 84 genes (Figure 5B; Supplementary file 1). RBM47-dependent 
splicing changes were confirmed via RT-PCR as shown for SLK, MDM4, LIMCH1, MBNL1 and SEC31A 
(Figure 5C, Figure 5—figure supplement 1).
By mapping normalized RBM47 CLIP tags associated with RBM47-dependent splicing changes 
on a composite transcript (Licatalosi et al., 2008) we generated an RNA binding map of consen-
sus binding sites within 1 kb of exon-intron boundaries, with respect to exon inclusion or exclusion 
(Figure 5D). The resulting normalized complexity map reveals enriched RBM47 binding in the 
vicinity of splice acceptor sites of the CA exon and 3′ CE for included alternative isoforms, while 
relative enrichment of RBM47 binding was seen at the 5′ CE splice donor and 3′CE splice acceptor 
of excluded isoforms.
RBM47 affects mRNA steady state levels
To further study the functional consequences of RBM47-mRNA binding events, we determined 
global steady state mRNA levels in the RBM47 expressing brain metastatic cells by RNA-seq. We 
took advantage of the clonal doxycycline-inducible cell line systems, which facilitated the analysis 
of RBM47 dose-dependence. First, genome-wide analyses showed that the mRNA level of several 
more genes correlated significantly with increasing concentrations of doxycycline in both cell lines 
expressing the wild type RBM47 (WT6 and WT10), when compared to cells expressing the mutant 
(Figure 6A). This result indicated that RBM47 elicits dose-dependent changes in mRNA levels. 
The correlation coefficients followed a pattern that suggested the existence of mRNA species that 
correlated both positively and negatively with wild type, but not mutant, RBM47 expression, that 
is few genes in MUT3 cells had correlation coefficients close to 1 or −1, whereas in WT6 and WT10 
cells such genes were abundant (Figure 6B). Encouraged by these observations, we looked for 
mRNAs that fulfilled the following criteria: (i) p-value of correlation less than 0.01 in both WT6 and 
WT10 cells, (ii) mRNA expression change detectable already at the lowest levels of RBM47 expres-
sion in both cell clones and (iii) no significant correlation with RBM47I281fs expression. This revealed 
a set of 102 mRNAs that were upregulated and 92 that were downregulated, respectively, in cells 
expressing the wild type RBM47 (Figure 6C, Figure 6—figure supplement 1A,B; Supplementary 
file 2). Importantly, these changes were observed already with the lowest expression level of 
RBM47 that was comparable or lower than those detected in endogenously RBM47 expressing 
cells (Figure 3—figure supplement 2D,E).
To determine whether the 194 RBM47-responsive genes displayed clinically meaningful expression 
patterns, we conducted an unsupervised hierarchical clustering analysis of the TCGA cohort of breast 
stringently purified, circularized and linearized using ApeI to bring the Illumina sequence into correct orientation 
with respect to the cloned fragment, and the samples PCR amplified and deep sequenced. (C) RBM47 HITS-CLIP is 
highly reproducible between replicate experiments at the level of unique CLIP tags per transcript. (D) Increasing 
the stringency of biologically reproducible RBM47 binding site definition reveals predominant binding in 3′UTRs 
and intronic regions of target transcripts, with the most robust binding (tags per binding site) evident in 3′UTRs.  
(E) Distribution of tags number per biologically reproducible cluster in coding and non-coding regions of RBM47-
targeted transcripts reveals a bimodal binding pattern between 3′UTRs and introns, with the latter having large 
numbers of reproducible yet less robust binding. (F) MEME analysis reveals an enrichment for polyU sequences 
(50 sites, p=2.4e−16) in the ±10 nt foot print region surrounding reproducible RBM47 deletion CIMS (357 sites with 
≥5 mutations, FDR ≤0.01, Zhang and Darnell, 2011). (G) Widespread RBM47 binding is seen in target tran-
scripts, as exemplified by binding patterns seen in the 3′UTRs of DKK1 and IL8.
DOI: 10.7554/eLife.02734.010
Figure 4. Continued
Genes and chromosomes | Human biology and medicine
Vanharanta et al. eLife 2014;3:e02734. DOI: 10.7554/eLife.02734 10 of 24
Research article
Figure 5. RBM47 regulates alternative splicing. (A) Schematic showing the method used to calculate alternative 
exon inclusion rates from paired-end RNA-seq data. 5′CE–5′ flanking constitutive exon, 3′CE–3′ flanking constitutive 
exon, 5′FI–5′ Flanking intron, 3′FI–3′ Flanking intron. (B) Scatter plot of all expressed alternatively spliced CA exons 
showing RBM47-dependent change in inclusion (black, ≥10 RNA-seq reads spanning exon–exon junctions, ΔI ≥|0.2|, 
p≤0.05) with orange points indicating RBM47-bound and included CA exons, and blue points indicating bound and 
excluded exons, respectively. CA exons were considered bound given a total of tags ≥10 in BC2 tags ≥5 clusters 
mapping to the region spanning the start of the 5′CE to the end of the 3′CE. p-values calculated by Fisher's exact 
test using total isoform 1 and total isoform 2 RNA-seq reads in each condition. (C) Left panel shows a section of the 
SLK transcript (blue) that includes a CA exon (grey box). The top two panels show RNA-seq data from WT10 (green) 
and control cells (red), with RBM47 HITS-CLIP tags mapping to the region shown beneath in black. Increased 
RNA-seq signal corresponding to the CA exon is seen in the presence of RBM47 expression, while robust binding 
is evident in the 5′FI. Independent RT-PCR validation of this splice is shown in the right panel, with IR calculated 
using ImageJ analysis of autoradiograms. (D) Normalized complexity map of RBM47-dependent alternative splicing 
Figure 5. Continued on next page
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cancer specimens. Two main clusters emerged, one of which harbored characteristics of the RBM47-
low phenotype (‘Cluster 2’, Figure 6—figure supplement 1C). First, this subgroup, Cluster 2, had 
significantly lower RBM47 expression levels when compared to Cluster 1 (Figure 6D). Second, the 
genes that were induced upon RBM47 reintroduction tended to have lower expression in Cluster 2, 
whereas genes with reduced expression level in the RBM47-expressing cells tended to show higher 
expression in Cluster 2 (Figure 6E). These observations validated in clinical tumor samples the RBM47-
dependent gene expression correlations identified in vitro.
To identify directly regulated targets of RBM47, we combined the mRNA expression data with 
the HITS-CLIP-derived RBM47 transcriptome-wide binding data. Of the 2498 strongest binding part-
ners with >100 tags per transcript (total tags in BC2 tags ≥10 clusters; Supplementary file 3), 25 were 
among the 102 RBM47-upregulated genes and 17 among the 92 RBM47-downregulated genes 
(Figure 6F), indicating no significant binding preference for either groups. This was reflected in the 
similar overall RBM47 binding profiles in both the up- and down-regulated genes (Figure 6G). Two of 
the top-scoring RBM47 binding mRNAs, IL8 and DKK1 (17,079 and 16,208 tags in clusters per gene, 
respectively, Figure 4G), were among the upregulated genes. This increase in mRNA levels was asso-
ciated with increased protein secretion as determined by ELISA, whereas VEGFA, the mRNA of which 
was bound but not upregulated by RBM47, showed no change in protein secretion (Figure 6H).
RBM47 modulates DKK1 mRNA stability
Nuclear RNA binding proteins typically function in large multiprotein complexes that regulate mRNA 
biogenesis (Dreyfuss et al., 2002). Our data from both genome-wide HITS-CLIP and RNA-seq anal-
ysis was compatible with RBM47 being a member of these RNA chaperone units. This suggested 
that RBM47 may not necessarily have a direct tumor suppressive signaling function. Rather, it raised 
the possibility that loss of RBM47, leading to subtle changes in multiple mRNAs, either through stabi-
lization, destabilization or alternative splicing, could be selected for if the net effect of both growth-
promoting and growth-inhibiting changes would be beneficial for cancer cells under the stress of 
dissemination to and colonizing distant organs. In line with this, both the up- and down-regulated 
target genes of RBM47, as well as the genes that were targets of RBM47-mediated alternative splic-
ing, contain genes that have previously been shown to either promote or inhibit tumor phenotypes 
(Supplementary file 1 and Supplementary file 3). For example, DKK1 (Bafico et al., 2004; Cowling 
et al., 2007; Mikheev et al., 2008), HTATIP2 (Zhao et al., 2007), HBP1 (Paulson et al., 2007; 
Li et al., 2011), MXI1 (Lahoz et al., 1994) and CASP7 (Hudson et al., 2013), all bound by RBM47 
and upregulated upon RBM47 reintroduction, have known tumor suppressive functions. Similarly, 
RBM47-induced splicing changes were seen in genes such as SLK (Roovers et al., 2009), MDM4 
(Wade et al., 2013) and TNC (Oskarsson et al., 2011), all of which are genes with known functions 
in cancer.
Focusing on DKK1, one of the most robustly bound RBM47 target transcripts identified by HITS-
CLIP, we investigated the possible role of RBM47 as a modulator of mRNA abundance. As predicted 
by our results in WT6 and WT10 cells, knockdown of RBM47 in two additional breast cancer cell lines 
expressing high levels of endogenous RBM47, SKBR3 and ZR-75-30, reduced DKK1 mRNA levels 
(Figure 7A, Figure 7—figure supplement 1A). This validated RBM47 as a modulator of DKK1 mRNA 
level in breast cancer cells.
The fact that RBM47 bound to DKK1 mRNA 3′UTR and increased DKK1 mRNA levels suggested the 
possibility that RBM47 had the capability of stabilizing DKK1 mRNA. We tested this by treating cancer 
cells with actinomycin D, a general inhibitor of transcription, and measuring DKK1 mRNA levels in the 
following hours. This demonstrated that wild type RBM47, but not the RBM47I281fs mutant, was able to 
increase the half-life of DKK1 mRNA by up to fourfold (Figure 7B).
of CA exons. Orange and blue peaks represent binding associated with RBM47-dependent exon inclusion and 
exclusion, respectively.
DOI: 10.7554/eLife.02734.011
The following figure supplements are available for figure 5:
Figure supplement 1. RBM47-dependent splicing events.
DOI: 10.7554/eLife.02734.012
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Figure 6. RBM47-induced changes in mRNA levels. (A) Distribution of p-values from correlation analysis of 
doxycycline concentration and gene expression for all genes in WT6, WT10 and MUT3 cell lines, respectively. 
Global gene expression determined by RNA-seq. (B) Distribution of correlation coefficients between doxycycline 
concentration and gene expression in WT6, WT10 and MUT3 cell lines, respectively. (C) Heat maps showing the 
top 102 positively (UP) correlated and 92 negatively (DOWN) correlated genes with RBM47 expression in WT6  
and WT10 cells. The expression of these genes does not correlate with RBM47I280fs expression in the MUT3 cells. 
(D) RBM47 mRNA expression in the TCGA cohort of breast cancer samples classified by the clusters shown in 
Figure 6—figure supplement 1C. p-value determined by two-tailed Student's t test. (E) Fold change between 
Cluster 1 and Cluster 2 shown for the 102 positively and 92 negatively correlated RBM47 target genes, respectively. 
Positive fold change shows higher expression in Cluster 2, which has lower expression of RBM47. The genes that 
are induced upon RBM47 reintroduction tend to have lower expression in Cluster 2, and the genes that show lower 
expression upon RBM47 reintroduction tend to have higher expression in Cluster 2. This is in line with the experi-
mental results shown in panel (C). P-value determined by two-tailed Student's t test. (F) Pie charts showing the 
fraction of target genes with more than 100 RBM47 tags for both the 102 positively and 92 negatively correlated 
RBM47 target genes. (G) Tags per transcript plotted for both the positively and negatively correlated RBM47 target 
genes that showed more than 1 tag. The only two binding partners with >104 tags represent DKK1 and IL8, 
respectively. (H) Secreted DKK1 and IL8 protein levels determined by ELISA in WT6 cells treated with the indicated 
doxycycline concentrations. VEGFA used as a control.
DOI: 10.7554/eLife.02734.013
The following figure supplements are available for figure 6:
Figure supplement 1. Transcriptomic signature of RBM47 reintroduction.
DOI: 10.7554/eLife.02734.014
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Figure 7. RBM47 modulates DKK1 mRNA stability. (A) RBM47 and DKK1 mRNA expression measured by quantita-
tive real-time RT-PCR in SKBR3 cells expressing either control vector (pGIPZ) or hairpins against RBM47 (shRNA1 
and shRNA2). Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (B) DKK1 mRNA 
stability determined by measuring mRNA levels by quantitative real-time RT-PCR in WT6, WT10 and MUT3 cells, 
treated with or without doxycycline, after inhibition of transcription with actinomycin D. Data normalized to time 
point 0. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. WT6: T1/2 Ctrl = 2.3 hr, 
T1/2 Dox = 9.8 hr; WT10: T1/2 Ctrl = 2.4 hr, T1/2 Dox = 5.4 hr; MUT3: T1/2 Ctrl = 2.1 hr, T1/2 Dox = 2.2 hr. (C) Schematic 
showing the locations of different DKK1 miR-constructs in relation to DKK1 genomic locus and RBM47 binding 
patterns. miRm and miRn target exon 1 that is not bound by RBM47. miRo, miRp and miRq target DKK1 3′UTR that 
is strongly bound by RBM47. (D) DKK1 mRNA expression measured by quantitative real-time RT-PCR in WT6 cells 
expressing either control vector (pGIPZ) or the five DKK1-targeting miR constructs shown in panel (C). Error bars 
represent 95% confidence intervals obtained from multiple PCR reactions. (E) DKK1 mRNA expression measured by 
quantitative real-time RT-PCR in WT6 cells expressing either control vector (pGIPZ) or the five DKK1-targeting miR 
constructs, with or without doxycycline treatment. Data normalized to the non-treated control for each cell line 
separately. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (F) DKK1 mRNA 
expression measured by quantitative real-time RT-PCR in WT10 cells expressing either control vector (pGIPZ) or the 
five DKK1-targeting miR constructs shown in panel (C). Error bars represent 95% confidence intervals obtained from 
multiple PCR reactions. (G) DKK1 mRNA expression measured by quantitative real-time RT-PCR in WT10 cells 
expressing either control vector (pGIPZ) or the five DKK1-targeting miR constructs, with or without doxycycline 
treatment. Data normalized to the non-treated control for each cell line separately. Error bars represent 95% 
confidence intervals obtained from multiple PCR reactions.
DOI: 10.7554/eLife.02734.015
The following figure supplements are available for figure 7:
Figure supplement 1. Effects of RBM47 knockdown on DKK1 mRNA.
DOI: 10.7554/eLife.02734.016
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RBM47 protects DKK1 3′UTR from destabilizing factors
As RBM47 binding to DKK1 was concentrated on the 3′UTR, a known region of regulatory activity 
(Zhou et al., 2012), we considered the possibility that RBM47 could compete with microRNAs or 
other mRNA destabilizing factors that target the 3′UTR (Bhattacharyya et al., 2006; Young et al., 
2012). To test this experimentally, we generated miR-30-based shRNA-miR constructs that tar-
geted different regions of the DKK1 transcript, two at the 5′ end with minimal RBM47 binding and 
three at the 3′ end with abundant RBM47 signal (Figure 7C; Fellmann et al., 2011). All constructs 
knocked the DKK1 transcript level down by 65–80% in the WT6 cells when no doxycycline was 
present (Figure 7D). The induction of RBM47 expression did not have a significant effect on the 
efficiency on the 5′-targeting shRNA-miRs (Figure 7E). In contrast, RBM47 inhibited the capability 
of the 3′-targeting shRNA-miRs to keep the DKK1 mRNA level down (Figure 7E). Similar observa-
tions were made with the WT10 cells (Figure 7F,G). Argonaute HITS-CLIP in the MDA231-BrM2 
cells (CBM et al., unpublished data) indicates robust binding to the DKK1 3′UTR, supporting the 
regulatory role of this region. We conclude that the effects of RBM47 on DKK1 mRNA levels may 
be due to the ability of RBM47 to protect this mRNA from destabilizing factors, possibly through 
direct interaction with the DKK1 mRNA.
RBM47 inhibits tumor progression by suppressing Wnt activity
DKK1 is an inhibitor of Wnt signaling, a pathway with a well-established role in regulating stem cell 
characteristics in both normal and malignant cells (Clevers and Nusse, 2012). Indeed, DKK1 as 
well as other Wnt antagonists have been shown to inhibit breast cancer progression (Bafico et al., 
2004; Cowling et al., 2007; Mikheev et al., 2008; Matsuda et al., 2009). The fact that RBM47 
was able to increase DKK1 secretion therefore suggested that RBM47 may also inhibit Wnt signal-
ing and consequently reduce the tumorigenic fitness of metastatic breast cancer cells. We first 
tested the effects of RBM47 on cancer cell Wnt responsiveness by treating WT6 cells with recom-
binant Wnt3A and subsequently measuring the expression of AXIN2, a common TCF/β-catenin 
target gene and a general marker of Wnt activity (Lustig et al., 2002; Clevers and Nusse, 2012). 
Doxycycline-induced expression of RBM47 in WT6 cells led to a dampened Wnt3A-dependent 
AXIN2 induction (Figure 8A). This inhibition of AXIN2 expression was at least partially dependent 
on DKK1 (Figure 8B). In agreement with these results, human breast cancers with low RBM47 
expression had in general higher levels of Wnt transcriptomic activity when compared to tumors 
with high RBM47 expression in the TCGA cohort (Figure 8C).
We then tested the possibility that RBM47 would suppress tumorigenesis by implanting low num-
bers of WT6 cells at the orthotopic site. The induction of RBM47 by doxycycline was able to signifi-
cantly delay the emergence of mammary tumors (Figure 8D), and the tumors that formed were 
smaller in size (Figure 8E). This observation was confirmed in WT10 cells (Figure 8—figure supple-
ment 1A). In line with this, inhibition of DKK1 expression in the MDA231-BrM2 cells promoted 
tumor formation in the orthotopic site (Figure 8F, Figure 8—figure supplement 1B). Finally, we 
used the two exon 1 DKK1 shRNAmiR constructs (Figure 7C) to reduce DKK1 levels in the WT6 cells 
(Figure 8—figure supplement 1C) and tested how this affected the brain metastatic ability of these 
cells in the presence of RBM47. Only 1/9 mice (16%) injected with control cells developed brain 
metastasis, whereas 8/17 mice (47%) inoculated with DKK1 RNAi construct transduced cells devel-
oped metastasis (Figure 8G,H). Taken together, these observations suggested that RBM47-
dependent suppression of tumor progression was partially mediated by its ability to increase the 
production of the Wnt antagonist DKK1, a secreted protein that can inhibit tumor phenotypes in 
metastatic cancer cells.
Discussion
Cancer genomes contain numerous genes with low-frequency mutations of unknown functional 
significance. We have studied one such gene, the previously uncharacterized RBM47, and demon-
strate that it has tumor suppressive functions in breast cancer. RBM47 acts as a multifunctional 
RBP modulating alternative splicing and the abundance of several mRNAs, which can lead to inhi-
bition of cancer progression (Figure 8I,J). These results highlight the significance of infrequent 
mutations in cancer, the importance of integrated experimental approaches to identify such func-
tionally relevant mutations, and the role of broadly targeted mRNA chaperones as determinants 
of cancer progression.
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Figure 8. RBM47 suppresses tumor progression via Wnt inhibition. (A) AXIN2 mRNA levels determined by 
quantitative real-time RT-PCR in WT6 cells treated with recombinant WNT3A in the presence of increasing 
concentrations of doxycycline. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. 
(B) Normalized level of AXIN2 mRNA inhibition as determined by quantitative real-time RT-PCR in WT6 cells 
transduced wither with control vector or shRNAmiR constructs targeting the first exon of DKK1. The cells were 
treated with recombinant WNT3A in the presence of increasing concentrations of doxycycline. Error bars represent 
95% confidence intervals obtained from multiple PCR reactions. (C) Wnt pathway activity assessed in the TCGA 
cohort of primary breast tumors, grouped by RBM47 expression tertiles (L, low; M, medium; H, high). Wnt signature 
value calculated as sum of z-scores for a curated set of 16 Wnt target genes in breast cancer. p-value determined 
by linear regression analysis. (D) Mammary tumor re-initiation assay. 5,000 WT6 cells implanted orthotopically in 
mice. RBM47 induced by doxycycline feed. Tumor growth detected by bioluminescence. p-value determined by 
the log-rank test. N = 20 tumors for each group. (E) Quantification of mammary tumor burden by in vivo biolumi-
nescence imaging on day 33 of the experiment shown in (D). Data normalized to day 0 for each tumor. p-value 
calculated by the Wilcoxon rank-sum test. (F) Quantification of mammary tumor burden by in vivo bioluminescence 
imaging in mice inoculated with 231-Brm2 cells transduced with either control (pGIPZ) or DKK1-targeting shRNAmiR 
constructs. Data normalized to day 0 for each tumor. p-value calculated by one-tailed Wilcoxon rank-sum test.  
(G) Quantification of ex vivo brain bioluminescence shown for mice inoculated intracardiacly with WT6 cells 
transduced with either control (pGIPZ) or DKK1-targeting shRNAmiR constructs in the presence of RBM47, that is 
doxycycline in diet. One out of 9 (11%) control mice developed robust brain metastasis whereas 8/17 (47%) mice in 
the DKK1 knockdown groups showed metastasis. p-value calculated by one-tailed Student's t test. (H) Representative 
Figure 8. Continued on next page
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RBM47 contains three classical RNA recognition motifs (RRM domains). The closest homologs of 
RBM47 are Apobec1 complementation factor (A1CF) and hnRNP-Q, which regulate RNA editing (Mehta 
et al., 2000) and splicing and transcript stability, respectively (Chen et al., 2008; Weidensdorfer 
et al., 2009). In general, RBPs bind to and influence the function and fate of both pre-mRNAs and 
mRNAs (Dreyfuss et al., 2002). They can operate in large multiprotein complexes that dynamically 
regulate all the steps of mRNA biogenesis, nuclear export, stability and translation. Individual subu-
nits of these complexes can therefore have diverse phenotypic roles depending on the exact protein 
complex they are in Chaudhury et al. (2010). Our observations on RBM47 are in line with these 
known general principles of RBP function.
Our data demonstrate widespread and reproducible RBM47 binding to target mRNAs predominantly 
in introns and 3′UTRs, with the most robust binding occurring in 3′UTRs. Recent RNA-compete studies 
have proposed a binding motif for RBM47 in vitro (Ray et al., 2013). Our in vivo HITS-CLIP data does 
not suggest a clear nucleotide binding specificity for exogenous Flag-tagged RBM47, although some 
preference was observed for polyU stretches around CIMS sites. It has been shown that the presence of 
a canonical motif is neither necessary nor sufficient to predict HITS-CLIP binding sites of FUS in both 
mouse and human brain (Lagier-Tourenne et al., 2012), while specific sites suggested by in vitro RNA 
selection experiments are not enriched in HITS-CLIP derived FMRP binding sites in vivo (Darnell et al., 
2011). This would suggest that other factors such as RNA accessibility, secondary structure or protein–
protein interactions may modulate RBM47 target choice (Li et al., 2014). Further work is therefore 
needed for a comprehensive understanding of the determinants of RBM47-mRNA interactions.
We find that RBM47 binds robustly to ∼2500 gene transcripts in human breast cancer cells, with 
only a subset showing steady state level change or alternative splicing upon RBM47 reintroduction. 
Given the stringent criteria used to define RBM47-bound and regulated targets and the generally low 
level of intronic RNA in a cell, it is likely that this subset is an underestimation of the number of RBM47-
regulated transcripts, and does not take into account the potential for regulatory events, such as 
re-localization, that may not alter steady state transcript levels. The complex interplay of RBPs in 
agonistic and antagonistic modulation of mRNA is becoming increasingly apparent. For example, the 
RRM-domain containing protein HuR modulates the destabilizing effects of miRNAs (Bhattacharyya 
et al., 2006; Kim et al., 2009; Young et al., 2012) and AUF1 (Zou et al., 2010) on common target 
transcripts. The data presented here suggest that target-specific RBM47 regulation may arise through 
modulation of accessibility of other factors to a common mRNA transcript.
RBM47 binds and regulates transcripts that encode for proteins of several different biological func-
tions. The effects of reduced RBM47 activity on cancer cell fitness, determined by the sum phenotypic 
output of all regulated target transcripts, may therefore vary depending on the context. Such pleiotropic 
effects could target multiple steps of cancer progression. Indeed, even though RBM47 loss was asso-
ciated with metastatic cancer clones in our model systems, evidence for selection against RBM47 was 
detected already in primary breast cancers. One of the most highly bound RBM47 mRNA targets, the 
secreted Wnt inhibitor DKK1, is stabilized by RBM47 and partially mediates RBM47 tumor suppressive 
function. Interestingly, rbm47 knockdown in zebra fish embryos leads to a headless phenotype medi-
ated via up-regulation of the wnt8a pathway (Guan et al., 2013). In addition to DKK1, our analysis 
identified a number of potential mediators of RBM47 effects for future studies.
images of coronal brain sections analyzed for GFP immunofluorescence from the experiment shown in panel  
(G). Lesion contours are marked in white. Arrowheads indicate the lesions shown in higher magnification on the 
right; a similar brain area is shown for the control group. Scale bar 500 μm. (I) At the global level, RBM47 binds to 
∼2500 target mRNAs. However, the abundance or alternative splicing of only a fraction of these change depending 
on RBM47 status. The target genes represent molecules from various signaling pathways. The net effect of growth 
promoting and inhibiting alterations determine whether RBM47 loss is beneficial for a particular cancer clone. (J) At 
the target mRNA level, the effects of RBM47 are dependent on the presence of other factors that modulate mRNA 
processing. Hence, the phenotype of RBM47 loss depends on the intracellular molecular milieu on a per transcript 
basis. This is exemplified by the interaction of RBM47 with DKK1 mRNA.
DOI: 10.7554/eLife.02734.017
The following figure supplements are available for figure 8:
Figure supplement 1. DKK1 as a mediator of RBM47-dependent tumor suppression.
DOI: 10.7554/eLife.02734.018
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From a general perspective, the present findings illuminate two concepts. First, we show that low-
frequency cancer mutations can give rise to tumorigenic phenotypes. Our work highlights the power of 
orthogonal approaches for the analysis of cancer genome resequencing data. Second, we show that loss 
of a broadly targeted and multifunctional RBP can increase the fitness of certain cancer cell clones in sup-
port of metastasis. This complements previous findings of RNA-binding proteins as mediators of oncogenic 
phenotypes (Karni et al., 2007; Richard et al., 2008; Sommer et al., 2011; Das et al., 2012; Wang et al., 
2013). Deregulation of RNA-binding proteins is thus emerging as a prominent source of complex transcrip-
tomic diversity that can serve as a platform for the selection of metastatic traits during tumor progression.
Materials and methods
Cell lines
The metastatic breast cancer cell lines have been previously described (Kang et al., 2003; Minn et al., 
2005; Bos et al., 2009). SKBR3, ZR-75-30 and HCC1954 cells were obtained from ATCC (Manassas, VA). 
For retrovirus and lentivirus production, GPG29 and 293T cells, respectively, were utilized. All cell lines 
were maintained under standard tissue culture conditions. Single cell-derived clones were isolated 
utilizing fluorescence-activated cell sorting from genetically engineered 231-BrM2 (WT10, MUT3) and 
CN34-BrM2 (WT6) cells.
cDNA expression and RNAi
For RBM47 restoration, RBM47 was cloned into the pBABE-puro retroviral expression vector. The 
RBM47I281fs was generated by site-directed mutagenesis. Virus was generated in the GPG29 packaging 
cells. For the generation of doxycycline-inducible expression constructs, both wild type and mutant 
FLAG-RBM47 were cloned into the pRetroX-Tight-Pur expression system (Clontech, Mountain View, CA).
For RNAi-mediated gene silencing, RBM47 pGIPZ shRNA constructs (clones V2LHS_176331 and 
V3LHS_393928, respectively) were obtained from Open Biosystems (Lafayette, CO). The DKK1 shRNAmiR 
constructs were designed based on the rules described by Fellmann et al. (2011) and cloned into the 













The pGIPZ empty vector was used as a control.
Animal studies
All animal experiments were performed in accordance with a protocol approved by MSKCC Institutional 
Animal Care and Use Committee. Lung metastasis assays were conducted in 5–7 week old female 
NOD/SCID mice. Brain metastasis and mammary tumor assays were carried out using 5–7 week old 
female athymic nude mice. In vivo bioluminescence imaging was performed using the IVIS Spectrum 
Xenogen machine (Caliper Life Sciences, Hopkinton, MA). For orthotopic mammary tumor assays, cells 
were mixed with Matrigel. Injections were confirmed and tumor growth was followed by biolumines-
cent imaging. Statistical significance of tumor and metastasis free survival was assessed by the log-
rank test. Differences in raw and normalized bioluminescence signal was assessed by the Student's 
t test and Wilcoxon rank-sum test, respectively. Brain images were acquired with a Leica SP5 up-right 
confocal microscope and Zeiss AxioVert 200 M using 20X and 5X objectives. Image analysis was per-
formed with Metamorph and ImageJ softwares.
mRNA and protein detection
Total RNA was extracted using PrepEase RNA spin kit (USB, Cleveland, OH). We used Transcriptor 
First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN) for cDNA synthesis. Quantitative PCR was 
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performed using predesigned Taqman gene expression assays (Life Technologies, Carlsbad, CA) and 
the 7900HT or ViiA 7 real-time PCR systems (Applied Biosystems/Life Technologies). TBP was used as 
a housekeeping control gene. mRNA stability was assessed by performing quantitative PCR after 
actinomycin D treatment. For immunoblotting, antibodies recognizing RBM47 (HPA006347; Sigma, 
St. Luis, MO), α-tubulin (11H10; Cell Signaling, Danvers, MA) and ACTB (Sigma) were utilized. 
Secondary antibodies were HRP (Pierce, Rockford, IL) or fluorescence (LiCor, Lincoln, NE) conjugated. 
Immunostaining for RBM47 (HPA006347; Sigma) was performed according to standard protocols in 
the MSKCC Molecular Cytology Core Facility on paraffin embedded tissue blocks. Secreted protein 
was detected by ELISA (R&D, Minneapolis, MN).
HITS-CLIP
231BrM2 tet-on FLAG-RBM47 cells were treated with 1 ng/ml doxycycline for 3 days before 254 nm 
UV crosslinking at 400 mJ/cm2 on a bed of ice (Stratalinker2400; Stratagene, La Jolla, CA). Samples 
were processed for HITS-CLIP as previously described (Licatalosi et al., 2008) using an anti-Flag anti-
body (F3165; Sigma), and omitting 3′ linker ligation in favor of direct labeling of protein-bound RNA 
with 32P-γ-ATP. Non-crosslinked cells were used as a negative control, with IPed Flag-RBM47 protein 
detected using a second anti-Flag antibody (F7425; Sigma). Purified RBM47-bound RNA fragments 
were polyA tailed (E-PAP; NEB), and reverse transcribed (Superscript III; Invitrogen, Carlsbad, CA) in 
the presence of Br-dUTP (Sigma). Unique polydT-NV RT-primers were used per replicate, containing 
Solexa sequences separated by an abasic furan (that serves as an ApeI cut site), a 6 nt degenerate 
region and a 6 nt index sequence to allow for multiplexing during sequencing.
 
RT Primer 1pGCACTGTTN6GATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAGACGGCATAC 
GAT20VN
RT Primer 2pGCGAAACTN6GATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAGACGGCATAC 
GAT20VN 
BrdU-cDNA was stringently purified by IP (sc-32323; Santa Cruz, Dallas, TX) using ProteinG dyna-
beads (Invitrogen), eluted from the beads via BrdU competitive elution (Sigma), and re-immunoprecip-
itated. cDNA was circularized on bead (CircLigase ssDNA Ligase II, Epicentre, Madison, WI), washed 
and digested with ApeI (NEB, Ipswich, MA) to relinearize. cDNAs were eluted from the beads by 
heating to 98C in Phusion HF Buffer (NEB), then PCR amplified using Phusion DNA polymerase (NEB) 
and SYBR Green I (Invitrogen) in an iQ5 real-time PCR machine in order to monitor amplification, with 
the samples being removed when the RFU signal reached ∼1000.
P5—aatgatacggcgaccaccgacaggttcagagttctacagtccgacg
P3—caagcagaagacggcata
PCR products were purified using MinElute columns (Qiagen, Valencia, CA) as per manufacturer's 
instructions and quantified using Quant-It (Invitrogen). cDNA was multiplexed and sequenced using 
Illumina Hi-Seq (small RNA sequencing primer—cgacaggttcagagttctacagtccgacgatc). All data analysis 
was done using the Galaxy platform (Hillman-Jackson et al., 2012), as previously described (Licatalosi 
et al., 2008; Chi et al., 2009; Darnell et al., 2011; Zhang and Darnell, 2011).
RT-PCR validation
RT-PCR validiation was carried out using total RNA from MDA231-BrM2 (Control) and WT10 cells 
(iScript, Bio-Rad, Accuprime Pfx Supermix 1, Life Technologies) as previously described (Licatalosi 
et al., 2012). In all cases lanes 1–3 contain an equal mixture of control and WT10 cell cDNA amplified 
at n-1, n and n+1 cycles, lane 4 contains an absence of reverse transcriptase control (−RT), with all 
other lanes corresponding to replicate samples of the indicated cell type amplified to n cycles. IR and 
ΔI calculated using ImageJ (Schneider et al., 2012).
Bioinformatic analysis
All analyses were conducted using R. Microarray data from human untreated tumor data sets 
(GSE2603 [Minn et al., 2005] and GSE2034 [Wang et al., 2005]) were preprocessed as described 
(Zhang et al., 2009). For the RNA-seq TCGA data set, normalized mRNA z-scores were downloaded 
from the TCGA cBio portal (Cerami et al., 2012). The microarray data from metastatic cell lines 
(Minn et al., 2005; Bos et al., 2009) were processed with GCRMA together with updated probe set 
definitions using R packages affy, gcrma and hs133ahsentrezgcdf (version 10). Unsupervised hierar-
chical clustering was performed using the function heatmap.2 with Pearson's correlation coefficient 
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as the similarity metric. For survival analysis, a Cox proportional hazards model was utilized as 
implemented in the coxph function in the R-package survival. For RNA-seq analysis of the cell lines, 
raw paired-end sequencing data were mapped to human genome (hg19 build) with STAR2.3.0 
(Dobin et al., 2013) using standard options. Reads mapped to each transcript were counted by 
HTSeq v0.5.4 (Anders and Huber, 2010) with default settings. The read count table was normalized 
to library size by DESeq (Anders and Huber, 2010). Correlation with RBM47 expression was assessed 
by Pearson's correlation coefficient utilizing the R functions cor and cor.test. Wnt pathway activity in 
clinical tumors was assessed utilizing a curated list of Wnt target genes in breast cancer (Matsuda 
et al., 2009) and calculating sums of z-scores for each tumor.
Accession numbers
RNA-seq and HITS-CLIP data have been deposited to the Gene Expression Omnibus under the acces-
sion numbers GSE53779 and GSE58381.
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